Lexicon Pharmaceuticals (LXRX) Key Ratios
$2.24
As on 04-Sep-2026 16:05EDT
Market cap
$997 Mln
Revenue (TTM)
$41 Mln
P/E Ratio
--
P/B Ratio
5.7
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -96.72 | -97.60 | -29.03 | 366.68 | 42.35 |
| EBIT | -5,431.99 | -623.63 | 46.51 | 16.42 | -205.26 |
| Net Profit | -2,946.50 | -1,077.09 | 49.33 | 15.29 | -209.92 |
| EPS | -2,685.99 | -911.66 | 54.11 | 21.10 | -183.09 |
| Book Value | -- | -- | -26.71 | -21.88 | -25.37 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -4,941.45 | -23,255.52 | -127.16 | -84.34 | -594.65 |
| Net Margin
| -- | -13,095.04 | -147.38 | -- | -- |
| Return on equity
| -125.29 | -105.85 | -43.34 | -39.72 | -167.66 |
| Return on Capital
| -69.15 | -67.95 | -- | -23.74 | -88.38 |
| Return on Assets
| -60.12 | -58.69 | -23.27 | -20.83 | -75.93 |
| Debt to Equity (x)
| -- | -- | 0.29 | 0.58 | 0.74 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Lexicon Pharmaceuticals (LXRX)
|
--
|
-23.74
|
-88.38
|
-95.33
|
-70.72
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-43.34
Lower than Peers by 2.94
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Lexicon Pharmaceuticals (LXRX)
|
-43.34
|
-39.72
|
-167.66
|
-168.50
|
-88.37
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-23.27
Higher than Peers by 7.70
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Lexicon Pharmaceuticals (LXRX)
|
-23.27
|
-20.83
|
-75.93
|
-83.60
|
-61.56
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Margin
-127.16
Lower than Peers by 43.54
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Lexicon Pharmaceuticals (LXRX)
|
-127.16
|
-84.34
|
-594.65
|
-14,145.35
|
-72,273.38
|
|
Peer Median
|
-83.62
|
--
|
--
|
--
|
--
|
Net Margin
-147.38
Lower than Peers by 54.71
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Lexicon Pharmaceuticals (LXRX)
|
-147.38
|
-101.08
|
-644.78
|
-14,710.88
|
-5,875.73
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Lower than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Lexicon Pharmaceuticals (LXRX)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
-29.03
Lower than Peers by 82.98
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Lexicon Pharmaceuticals (LXRX)
|
-29.03
|
0.60
|
24.81
|
7.66
|
-0.53
|
|
Peer Median
|
53.95
|
--
|
--
|
--
|
--
|
EBIT Growth
46.51
Higher than Peers by 47.31
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Lexicon Pharmaceuticals (LXRX)
|
46.51
|
77.27
|
-8.52
|
-69.53
|
-15.53
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
49.33
Higher than Peers by 56.63
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Lexicon Pharmaceuticals (LXRX)
|
49.33
|
74.88
|
-13.15
|
-73.74
|
-16.16
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
EPS Growth
54.11
Higher than Peers by 39.46
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Lexicon Pharmaceuticals (LXRX)
|
54.11
|
0.75
|
0.23
|
-0.34
|
0.08
|
|
Peer Median
|
14.65
|
--
|
--
|
--
|
--
|
Book Value Growth
12.01
Higher than Peers by 22.18
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Lexicon Pharmaceuticals (LXRX)
|
12.01
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.18
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.29
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Lexicon Pharmaceuticals (LXRX)
|
0.29
|
0.58
|
0.74
|
1.14
|
0.47
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.01
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Lexicon Pharmaceuticals (LXRX)
|
0.01
|
0.06
|
0.01
|
0.01
|
0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
13.37
Higher than Peers by 7.56
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Lexicon Pharmaceuticals (LXRX)
|
13.37
|
4.88
|
5.44
|
5.60
|
6.08
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
13.29
Higher than Peers by 7.59
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Lexicon Pharmaceuticals (LXRX)
|
13.29
|
4.87
|
5.44
|
5.58
|
6.08
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
-6.29
Lower than Peers by 4.20
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Lexicon Pharmaceuticals (LXRX)
|
-6.29
|
-5.04
|
-11.86
|
-13.00
|
-36.14
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
3.96
Lower than Peers by 15.18
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Lexicon Pharmaceuticals (LXRX)
|
3.96
|
4.79
|
11.17
|
83.89
|
20.14
|
|
Peer Median
|
19.14
|
--
|
--
|
--
|
--
|
Asset Turnover
0.16
Higher than Peers by 0.09
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Lexicon Pharmaceuticals (LXRX)
|
0.16
|
0.21
|
0.12
|
0.01
|
0.00
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Lexicon Pharmaceuticals (LXRX)
|
--
|
21.48
|
26.34
|
157.45
|
55.18
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Lexicon Pharmaceuticals (LXRX)
|
--
|
341.26
|
181.44
|
1.18
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Lexicon Pharmaceuticals (LXRX)
|
--
|
11,919.95
|
8,653.93
|
76.75
|
67.97
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Lexicon Pharmaceuticals (LXRX)
|
--
|
-11,557.21
|
-8,446.15
|
81.87
|
-12.79
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Lexicon Pharmaceuticals (LXRX)
|
--
|
-8.30
|
-1.33
|
-2.12
|
-3.54
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
5.71
Higher than Peers by 0.53
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Lexicon Pharmaceuticals (LXRX)
|
5.71
|
3.89
|
1.83
|
4.02
|
3.08
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Lexicon Pharmaceuticals (LXRX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
16.57
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Lexicon Pharmaceuticals (LXRX)
|
16.57
|
-9.28
|
-0.75
|
-1.83
|
-2.77
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
997
Higher than Peers by 851
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Lexicon Pharmaceuticals (LXRX)
|
997
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|